Ask AI
ProCE Banner Activity

AXSANA/EUBREAST 3(R): Primary Analysis of More vs Less Invasive Axillary Surgical Staging in Patients With Breast Cancer Downstaged From Clinically Node+ to Node- After Neoadjuvant Chemotherapy

Conference Coverage
Slideset

AXSANA/EUBREAST 3(R) demonstrates that axillary RFS at 3 years following SLNB, TAD, or TLNB is excellent and noninferior to outcomes with ALND in patients converted to ycN0 from cN+ after neoadjuvant therapy.

Released: December 19, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify subpopulations of patients with breast cancer most likely to benefit from a specific treatment plan based on predictive biomarkers

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with breast cancer
  • Evaluate new data on novel agents and therapeutic approaches for patients with breast cancer